Stability-Indicating HPLC Method for MPA in Bulk Drug and Injection Formulation

Analytical Test

Identification

Analytical Technique

HPLC

System Suitability

Internal standard method with progesterone as internal standard.

Experimental Setting Value
HPLC Agilent 1100 series pump, solvent degasser, autosampler, DAD detector
Column 150 x 4.6 mm, 5 μm Hichrom C18
Mobile Phase 65:35 v/v methanol/acetate buffer (0.02 M sodium acetate adjusted to pH 5.0 with glacial acetic acid)
Flow Rate 1.0 mL/min
Column Temperature 35° C
Detection λ 245 nm
Injection Volume 20 μL
Standard Stock Solutions 0.5 mg MPA and progesterone (PG) in mobile phase. Working solutions prepared by diluting stock solutions with the mobile phase to contain 100-300 μg/mL of MPA and 150 μg/mL PG as internal standard. Megestrol acetate (MGA) added to the standard solution for a purity test of bulk drug. Resolution should be not less than 1.5.
Sample Preparation Injectable suspensions from 20 vials were pooled and shaken on mechanical shaker for 30 min. A portion of the suspension equivalent to 50 mg MPA was weighed and transferred to a 50 mL volumetric flask. 10 mL methanol added. Shaken for 10 min, then adjusted to volume and mixed well. A 2 mL aliquot is transferred to a 10 mL volumetric flask containing 1500 μg internal standard. Sample diluted to volume with mobile phase and filtered through a 0.45 μm nylon syringe filter.

References

  1. Burana-osot, Jankana; Ungboriboonpisal, Sooksri; and Sriphong, Lawan. A stability-indicating HPLC method for medroxyprogesterone acetate in bulk drug and injection formulation. Journal of Pharmaceutical and Biomedical Analysis. 2006; 40:1068-1072.
  2. (View all citations for this reference)